Literature DB >> 27153849

Absence of TERT promoter mutations in pituitary adenomas.

C S Martins1, M de Castro2, R T Calado2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27153849     DOI： 10.1007/s40618-016-0479-8

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  5 in total

1.  Frequency of TERT promoter mutations in human cancers.

Authors:  João Vinagre; Ana Almeida; Helena Pópulo; Rui Batista; Joana Lyra; Vasco Pinto; Ricardo Coelho; Ricardo Celestino; Hugo Prazeres; Luis Lima; Miguel Melo; Adriana Gaspar da Rocha; Ana Preto; Patrícia Castro; Ligia Castro; Fernando Pardal; José Manuel Lopes; Lúcio Lara Santos; Rui Manuel Reis; José Cameselle-Teijeiro; Manuel Sobrinho-Simões; Jorge Lima; Valdemar Máximo; Paula Soares
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 2.  Telomerase and the endocrine system.

Authors:  Furio Pacini; Silvia Cantara; Marco Capezzone; Stefania Marchisotta
Journal:  Nat Rev Endocrinol       Date:  2011-03-29       Impact factor: 43.330

3.  Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system.

Authors:  Christian Koelsche; Felix Sahm; David Capper; David Reuss; Dominik Sturm; David T W Jones; Marcel Kool; Paul A Northcott; Benedikt Wiestler; Katja Böhmer; Jochen Meyer; Christian Mawrin; Christian Hartmann; Michel Mittelbronn; Michael Platten; Benjamin Brokinkel; Marcel Seiz; Christel Herold-Mende; Andreas Unterberg; Jens Schittenhelm; Michael Weller; Stefan Pfister; Wolfgang Wick; Andrey Korshunov; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2013-10-24       Impact factor: 17.088

4.  Telomere length and telomerase expression in pituitary tumors.

Authors:  C S Martins; B A Santana-Lemos; F P Saggioro; L Neder; H R Machado; A C Moreira; R T Calado; M de Castro
Journal:  J Endocrinol Invest       Date:  2015-05-08       Impact factor: 4.256

5.  TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas.

Authors:  Chen Chen; Sheng Han; Lingxuan Meng; Zhonghua Li; Xue Zhang; Anhua Wu
Journal:  PLoS One       Date:  2014-06-17       Impact factor: 3.240
  5 in total
  2 in total

1.  Alternative Lengthening of Telomeres (ALT) and Telomerase Reverse Transcriptase Promoter Methylation in Recurrent Adult and Primary Pediatric Pituitary Neuroendocrine Tumors.

Authors:  Hiba Alzoubi; Simone Minasi; Francesca Gianno; Manila Antonelli; Francesca Belardinilli; Felice Giangaspero; Marie-Lise Jaffrain-Rea; Francesca Romana Buttarelli
Journal:  Endocr Pathol       Date:  2022-01-06       Impact factor: 3.943

Review 2.  Telomere Maintenance Mechanisms in Cancer.

Authors:  Tiago Bordeira Gaspar; Ana Sá; José Manuel Lopes; Manuel Sobrinho-Simões; Paula Soares; João Vinagre
Journal:  Genes (Basel)       Date:  2018-05-03       Impact factor: 4.096
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.